OTUB2/ALYREF axis modulates the docetaxel resistance of castration-resistant prostate cancer via upregulating ABCG4-mediated drug efflux
International Journal of Biological Sciences · 2026
DOI: 10.7150/ijbs.126319 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Biological Sciences, 2026. Verfasst von Zhi-Bin Ke und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology, Urology Research Institute, the First Affiliated Hospital, Fujian Medical University, Fuzhou 350005, China. Hauptthemen laut MEDLINE: Docetaxel, Prostatic Neoplasms, Castration-Resistant, ATP Binding Cassette Transporter, Subfamily G. Die Arbeit wurde bisher 3-mal zitiert (Crossref). Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Docetaxel (DTX) is a standard chemotherapy agent for castration-resistant prostate cancer (CRPC); however, DTX resistance remains a major clinical challenge, and the underlying molecular mechanisms are not fully understood. In our study, it was found that OTUB2 was highly expressed in DTX-resistant CRPC and could be served as a key driver of DTX resistance. Mechanistically, OTUB2 stabilizes the m5C reader ALYREF by removing its K48-linked polyubiquitin chains, leading to increased ALYREF protein levels. And then, ALYREF enhances the mRNA stability and expression of ABCG4, thereby promoting ATP-dependent efflux of DTX. Moreover, the expression of OTUB2 mRNA and protein could be regulated by FOXD3-AS1 derived from cancer-associated fibroblasts (CAFs). More importantly, treatment with OTUB2 inhibitor (OTUB2-IN-1) resensitized resistant CRPC to DTX. Together, our findings establish OTUB2 as a novel driver of DTX resistance in CRPC and highlight the role of CAFs-derived FOXD3-AS1 and OTUB2/ALYREF/ABCG4 axis in modulating DTX resistance of CRPC.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Urology, Urology Research Institute, the First Affiliated Hospital, Fujian Medical University, Fuzhou 350005, China.
- Department of Urology, National Regional Medical Center, Binhai Campus of the First Affiliated Hospital, Fujian Medical University, Fuzhou 350212, China.
- Fujian Key Laboratory of Tumor Immunotherapy, the First Affiliated Hospital, Fujian Medical University, Fuzhou 350005, China.
Zitieren
APA
Ke, Z. B., Chen, J. Y., Lin, B., Chen, C. R., Xue, Y. T., Sun, J. B., Yan, Z. H., Zhao, Y. X., Liu, M. X., Wang, Z., Xue, X. Y., Zheng, Q. S., Wei, Y., & Xu, N. (2026). OTUB2/ALYREF axis modulates the docetaxel resistance of castration-resistant prostate cancer via upregulating ABCG4-mediated drug efflux. International Journal of Biological Sciences. https://doi.org/10.7150/ijbs.126319
Vancouver
Ke ZB, Chen JY, Lin B, Chen CR, Xue YT, Sun JB, et al. OTUB2/ALYREF axis modulates the docetaxel resistance of castration-resistant prostate cancer via upregulating ABCG4-mediated drug efflux. International Journal of Biological Sciences. 2026. doi:10.7150/ijbs.126319
BibTeX
@article{Ke2026,
author = {Ke, Zhi-Bin and Chen, Jia-Yin and Lin, Bin and Chen, Chao-Ran and Xue, Yu-Ting and Sun, Jiang-Bo and Yan, Zi-Heng and Zhao, Yu-Xuan and Liu, Meng-Xin and Wang, Zhen and Xue, Xue-Yi and Zheng, Qing-Shui and Wei, Yong and Xu, Ning},
title = {OTUB2/ALYREF axis modulates the docetaxel resistance of castration-resistant prostate cancer via upregulating ABCG4-mediated drug efflux},
journal = {International Journal of Biological Sciences},
year = {2026},
doi = {10.7150/ijbs.126319}
}
EUVIMED